China NMPA Drug Inspection - Sichuan Haobo Pharmaceutical Co., Ltd. - Cockscomb

On January 15, 2021, the Chongqing Municipal Drug Administration published results from a series of drug sampling inspections aimed at ensuring public safety and market regulation. The inspections identified seven batches of traditional Chinese medicine products that failed to comply with the 2015 Edition of the Chinese Pharmacopoeia. Five companies were implicated in the findings: Sichuan Tongshantang Traditional Chinese Medicine Pieces Co., Ltd., Sichuan Haobo Pharmaceutical Co., Ltd., Bozhou Zhang Zhongjing Traditional Chinese Medicine Pieces Co., Ltd., Sichuan Yunbotang Pharmaceutical Co., Ltd., and Chengdu Renjihong Pharmaceutical Co., Ltd. The primary violations involved failure to meet safety and quality benchmarks, specifically regarding organochlorine pesticide residues in American ginseng, excessive ash content in raw Typhae pollen, and non-compliance in physical appearance, content determination, and overall properties for products like honeysuckle and dried dendrobium. In response, the Chongqing Municipal Drug Administration has ordered relevant departments to implement immediate control measures. These required actions include the sealing and seizing of non-compliant inventory, the suspension of sales, and the formal recall of all affected batches. The authorities will continue to process these cases under current pharmaceutical laws to maintain strict quality standards within the drug supply chain.